MedPath

Nifedipine

Generic Name
Nifedipine
Brand Names
Adalat, Afeditab CR, Nifediac, Nifedical, Procardia
Drug Type
Small Molecule
Chemical Formula
C17H18N2O6
CAS Number
21829-25-4
Unique Ingredient Identifier
I9ZF7L6G2L
Background

Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to nicardipine. Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972. Since nifedipine's development, second and third generation dihydropyridines have been developed with slower onsets and longer durations of action. The most popular of the third generation dihydropyridines is amlodipine.

Nifedipine was granted FDA approval on 31 December 1981.

Indication

Nifedipine capsules are indicated to treat vasospastic angina and chronic stable angina. Extended release tablets are indicated to treat vasospastic angina, chronic stable angina, and hypertension.

Associated Conditions
Achalasia, Chronic Stable Angina Pectoris, Fissure;Anal, Hypertension, Hypertensive Emergency, Premature Labour, Proctalgia, Pulmonary Edemas, Pulmonary Hypertension (PH), Raynaud's Phenomenon, Ureteral Calculus, Vasospastic Angina
Clinical Trials
Related News

An Open Label Study to Examine the Effect of Coated Nifedipine Suppositories on Anal Pressure in Healthy Subjects

Phase 1
Completed
Conditions
Anal Resting Pressure
Interventions
First Posted Date
2009-01-01
Last Posted Date
2009-04-07
Lead Sponsor
RDD Pharma Ltd
Registration Number
NCT00816205
Locations
🇮🇱

Dept of Gastroeneterology, Asaf Harofe Medical Center, Zrifin, Israel

Tocolysis for Preterm Labor

Not Applicable
Completed
Conditions
Preterm Labor
Interventions
Drug: 1 Magnesium Sulfate
First Posted Date
2008-12-18
Last Posted Date
2013-04-04
Lead Sponsor
University of Mississippi Medical Center
Target Recruit Count
301
Registration Number
NCT00811057
Locations
🇺🇸

The Winfred L. Wiser Hospital for Women and Infants at the University of Mississippi Medical Center, Jackson, Mississippi, United States

Effects Of Sitaxsentan On Proteinuria, 24-Hour Blood Pressure, And Arterial Stiffness In Chronic Kidney Disease Subjects

Phase 2
Completed
Conditions
Chronic Kidney Disease
Interventions
Drug: Placebo
Drug: Open
First Posted Date
2008-12-18
Last Posted Date
2023-07-06
Lead Sponsor
Pfizer
Target Recruit Count
27
Registration Number
NCT00810732
Locations
🇬🇧

Clinical Research Centre and Pharmacology Unit, Edinburgh, Scotland, United Kingdom

🇬🇧

the University of Edinburgh, Western General Hospital, Department of Medical Sciences, Edinburgh, Scotland, United Kingdom

Nifedipine (Adalat CR, BAY A1040) High Dose PK/PD Study

First Posted Date
2008-10-08
Last Posted Date
2015-06-08
Lead Sponsor
Bayer
Target Recruit Count
35
Registration Number
NCT00768560

Endothelin Receptor Antagonism in Proteinuric Nephropathy

Phase 1
Completed
Conditions
Chronic Kidney Disease
Proteinuria
Interventions
Drug: 0.9 % saline
First Posted Date
2008-07-25
Last Posted Date
2008-07-25
Lead Sponsor
University of Edinburgh
Target Recruit Count
22
Registration Number
NCT00722215
Locations
🇬🇧

Clinical Research Centre, Western General Hospital, Edinburgh, Scotland, United Kingdom

Adalat XL vs Diltiazem on Proteinuria and Blood Pressure in Hypertensive Diabetic Patients

Phase 3
Withdrawn
Conditions
Hypertension
Diabetic Nephropathies
Interventions
First Posted Date
2008-07-11
Last Posted Date
2012-11-16
Lead Sponsor
Bayer
Registration Number
NCT00713011

Alfuzosin for Medical Expulsion Therapy of Ureteral Stones

Phase 3
Conditions
Kidney Stones
Interventions
First Posted Date
2008-07-11
Last Posted Date
2012-04-27
Lead Sponsor
United States Naval Medical Center, San Diego
Target Recruit Count
240
Registration Number
NCT00713739
Locations
🇺🇸

Naval Medical Center San Diego, San Diego, California, United States

Oral Nifedipine to Treat Iron Overload

Phase 1
Completed
Conditions
Iron Overload
Thalassemia
Hemochromatosis
First Posted Date
2008-07-10
Last Posted Date
2017-07-02
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Target Recruit Count
6
Registration Number
NCT00712738
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Effects of Adalat LA and Coracten on Drug Levels, Blood Pressure, and Heart Rate in Fed Patients With Hypertension

Phase 4
Completed
Conditions
Hypertension
Interventions
Drug: Coracten
First Posted Date
2008-05-06
Last Posted Date
2014-12-19
Lead Sponsor
Bayer
Target Recruit Count
43
Registration Number
NCT00672113

Black Education and Treatment of Hypertension (BEAT HTN)

First Posted Date
2008-04-21
Last Posted Date
2012-12-04
Lead Sponsor
Creighton University
Target Recruit Count
99
Registration Number
NCT00661895
Locations
🇺🇸

Creighton Community Health Center, Omaha, Nebraska, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy